AU2008237296B2 - Methods for inhibiting the binding of endosialin to ligands - Google Patents

Methods for inhibiting the binding of endosialin to ligands Download PDF

Info

Publication number
AU2008237296B2
AU2008237296B2 AU2008237296A AU2008237296A AU2008237296B2 AU 2008237296 B2 AU2008237296 B2 AU 2008237296B2 AU 2008237296 A AU2008237296 A AU 2008237296A AU 2008237296 A AU2008237296 A AU 2008237296A AU 2008237296 B2 AU2008237296 B2 AU 2008237296B2
Authority
AU
Australia
Prior art keywords
endosialin
cells
antibody
cell
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008237296A
Other languages
English (en)
Other versions
AU2008237296A1 (en
Inventor
Luigi Grasso
Nicholas C. Nicolaides
Philip M. Sass
Brian E. Tomkowicz
Yuhong Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Inc
Original Assignee
Eisai Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Inc filed Critical Eisai Inc
Publication of AU2008237296A1 publication Critical patent/AU2008237296A1/en
Application granted granted Critical
Publication of AU2008237296B2 publication Critical patent/AU2008237296B2/en
Assigned to EISAI, INC. reassignment EISAI, INC. Request for Assignment Assignors: MORPHOTEK, INC.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Flanged Joints, Insulating Joints, And Other Joints (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2008237296A 2007-04-05 2008-04-04 Methods for inhibiting the binding of endosialin to ligands Ceased AU2008237296B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US91036207P 2007-04-05 2007-04-05
US60/910,362 2007-04-05
US98002607P 2007-10-15 2007-10-15
US60/980,026 2007-10-15
PCT/US2008/059374 WO2008124570A1 (en) 2007-04-05 2008-04-04 Methods for inhibiting the binding of endosialin to ligands

Publications (2)

Publication Number Publication Date
AU2008237296A1 AU2008237296A1 (en) 2008-10-16
AU2008237296B2 true AU2008237296B2 (en) 2013-07-04

Family

ID=39714208

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008237296A Ceased AU2008237296B2 (en) 2007-04-05 2008-04-04 Methods for inhibiting the binding of endosialin to ligands

Country Status (20)

Country Link
US (4) US7807382B2 (OSRAM)
EP (2) EP2620451B1 (OSRAM)
JP (2) JP5825784B2 (OSRAM)
KR (1) KR101529334B1 (OSRAM)
CN (1) CN101918446B (OSRAM)
AU (1) AU2008237296B2 (OSRAM)
BR (1) BRPI0809665B8 (OSRAM)
CA (1) CA2682726C (OSRAM)
CY (2) CY1115370T1 (OSRAM)
DK (2) DK2620451T3 (OSRAM)
ES (2) ES2606906T3 (OSRAM)
HR (2) HRP20140266T1 (OSRAM)
HU (1) HUE031269T2 (OSRAM)
LT (1) LT2620451T (OSRAM)
MX (1) MX2009010701A (OSRAM)
PL (2) PL2137217T3 (OSRAM)
PT (2) PT2620451T (OSRAM)
RS (2) RS55447B1 (OSRAM)
SI (2) SI2620451T1 (OSRAM)
WO (1) WO2008124570A1 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006116451A2 (en) 2005-04-22 2006-11-02 Morphotek, Inc. Antibodies with immune effector activity and that internalize in endosialin-positive cells
PL2137217T3 (pl) * 2007-04-05 2014-08-29 Eisai Inc Sposoby hamowania wiązania endosialiny z ligandami
WO2009126725A1 (en) * 2008-04-09 2009-10-15 The Regents Of The University Of Michigan Method of modulating neovascularization
US20100260769A1 (en) * 2009-04-09 2010-10-14 Morphotek, Inc. Endosialin binding molecules
WO2011060233A1 (en) 2009-11-11 2011-05-19 The Trustees Of The University Of Pennsylvania Anti-tem1 antibodies and uses thereof
US20130305396A1 (en) 2010-09-29 2013-11-14 Luigi Grasso Engineered human endosialin-expressing rodents
EP2831114B1 (en) * 2012-03-30 2019-05-08 Eisai R&D Management Co., Ltd. Tem-1 diagnostic antibodies
WO2013162748A1 (en) * 2012-04-27 2013-10-31 The Trustees Of The University Of Pennsylvania Anti-tumor endothelial marker-1 (tem1) antibody variants and uses thereof
HK1219980A1 (zh) 2013-03-09 2017-04-21 Baylor College Of Medicine 靶向血管的t细胞疗法
GB201702926D0 (en) * 2017-02-23 2017-04-12 Univ Birmingham Modulators
IL272246B1 (en) 2017-07-28 2025-09-01 Applied Therapeutics Inc Derivatives of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as aldose reductase inhibitors in treating galactosemia or preventing complications associated with galactosemia
CN110531077B (zh) * 2018-05-25 2023-07-07 荣昌生物制药(烟台)股份有限公司 间皮素免疫组化检测试剂盒
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
MX2021013511A (es) 2019-05-07 2022-02-23 Univ Miami Tratamiento y deteccion de neuropatias heredadas y trastornos asociados.
CN111026023A (zh) * 2020-01-12 2020-04-17 安徽楚江科技新材料股份有限公司 基于s7-400控制系统的铜带轧机PLC组态方法
CN116790744B (zh) * 2023-06-30 2024-04-26 浙江大学 一种缺血性心脏病晚期纤维化干预靶点及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005086713A2 (en) * 2004-03-04 2005-09-22 Kirin Brewery Co., Ltd. Role of human endothelial precursor cells and vascular pericytes tumor in angiogenesis

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5342757A (en) 1992-11-13 1994-08-30 Ludwig Institute For Cancer Research Monoclonal antibodies which specifically binds to endosialin, a 165 Kd glycoprotein found on tumor vascular endothelium, and uses thereof
CA2154266A1 (en) 1993-02-05 1994-08-18 John F. Codington Human carcinoma antigen (hca), hca antibodies, hca immunoassays, methods of imaging and therapy
CA2185116A1 (en) 1994-03-08 1995-09-14 Thomas P. Wallace Recombinant humanized anti-fb5 antibodies
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US6146894A (en) 1998-04-14 2000-11-14 The Johns Hopkins University Method for generating hypermutable organisms
US6263223B1 (en) 1998-09-09 2001-07-17 The United States Of America As Represented By The Secretary Of The Army Method for monitoring arterial oxygen saturation
EP1283905A2 (en) * 2000-03-15 2003-02-19 Epigenomics AG Diagnosis of diseases associated with the cell cycle
US7402660B2 (en) * 2000-08-02 2008-07-22 The Johns Hopkins University Endothelial cell expression patterns
JP5036119B2 (ja) 2001-01-15 2012-09-26 モーフオテク・インコーポレーテツド ミスマッチ修復の化学阻害剤
US20040043928A1 (en) * 2001-08-02 2004-03-04 Ramesh Kekuda Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20030124579A1 (en) * 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20040014058A1 (en) * 2001-10-05 2004-01-22 Alsobrook John P. Novel human proteins, polynucleotides encoding them and methods of using the same
US20060127902A1 (en) * 2002-08-15 2006-06-15 Genzyme Corporation Brain endothelial cell expression patterns
AU2003298786A1 (en) * 2002-11-26 2004-06-18 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
EP1599503B1 (en) 2003-03-04 2010-12-29 Kirin Beer Kabushiki Kaisha Endothelial cell specific antibodies and uses thereof
WO2006017759A2 (en) 2004-08-05 2006-02-16 Kirin Brewery Co., Ltd. Tumor endothelial marker-1 (tem1) binding antibodies and uses thereof
WO2006029045A2 (en) 2004-09-03 2006-03-16 Kirin Brewery Co., Ltd. Endothelial cell specific antibodies and uses thereof
WO2006032705A2 (en) * 2004-09-23 2006-03-30 Guerbet Contrast agents encapsulating systems for cest imaging
CA2590583A1 (en) 2004-12-03 2006-06-08 Morphotek, Inc. Use of endosialin binding proteins to isolate endosialin positive cells
CN101175862A (zh) * 2005-02-10 2008-05-07 肿瘤疗法科学股份有限公司 诊断膀胱癌的方法
WO2006116451A2 (en) 2005-04-22 2006-11-02 Morphotek, Inc. Antibodies with immune effector activity and that internalize in endosialin-positive cells
US7315372B1 (en) * 2005-09-29 2008-01-01 The United States Of America As Represented By The Secretary Of The Navy Instrument using near-field intensity correlation measurements for characterizing scattering of light by suspensions
DE102005050933A1 (de) * 2005-10-21 2007-04-26 Justus-Liebig-Universität Giessen Erfindung betreffend Expressionsprofile zur Vorhersage von septischen Zuständen
US7908090B2 (en) * 2005-11-30 2011-03-15 The Board Of Trustees Of The Leland Stanford Junior University Signatures for human aging
CN101336300A (zh) * 2005-12-16 2008-12-31 健泰科生物技术公司 神经胶质瘤的诊断、预后和治疗方法
WO2008084331A2 (en) 2006-06-21 2008-07-17 Hopitaux Universitaires De Geneve Biomarkers for renal disorders
EP2041307A2 (en) * 2006-07-13 2009-04-01 Siemens Healthcare Diagnostics GmbH Prediction of breast cancer response to taxane-based chemotherapy
WO2008009132A1 (en) * 2006-07-21 2008-01-24 The Governors Of The University Of Alberta Tissue rejection
EP2069535B1 (en) 2006-08-11 2013-04-10 Johns Hopkins University Consensus coding sequences of human breast and colorectal cancers
US20080300170A1 (en) * 2006-09-01 2008-12-04 Cohava Gelber Compositions and methods for diagnosis and treatment for type 2 diabetes
US20100092476A1 (en) * 2006-11-17 2010-04-15 Hanash Samir M Pancreatic cancer biomarkers
WO2008097908A2 (en) 2007-02-05 2008-08-14 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and prognosing lung cancer
WO2008101118A2 (en) 2007-02-14 2008-08-21 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A gene expression signature identifying pro-angiogenic genes in ovarian tumor endothelial cell isolates
PL2137217T3 (pl) * 2007-04-05 2014-08-29 Eisai Inc Sposoby hamowania wiązania endosialiny z ligandami
EP1986010A1 (en) 2007-04-05 2008-10-29 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Methods and tools for discriminating colorectal adenomas and adenocarcinomas
US9186405B2 (en) 2007-08-16 2015-11-17 The Royal Institution For The Advancement Of Learning/Mcgill University Tumor cell-derived microvesicles
DK2245199T3 (da) * 2008-02-01 2014-02-03 Gen Hospital Corp Anvendelse af mikrovesikler i diagnosticering, prognosticering og behandling af medicinske sygdomme og tilstande
WO2009105549A2 (en) 2008-02-19 2009-08-27 Oncomethylome Sciences Sa Detection and prognosis of lung cancer
US20110117111A1 (en) 2008-03-26 2011-05-19 Johns Hopkins University Microrna-based diagnostic testing and therapies for inflammatory bowel disease and related diseases
US20100092470A1 (en) * 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
WO2010045714A1 (en) 2008-10-20 2010-04-29 University Health Network Methods and compositions for the detection of ovarian cancer
CA2749601C (en) 2009-01-14 2020-07-21 Stephen M. Hewitt Ratio based biomarkers and methods of use thereof
US20100260769A1 (en) * 2009-04-09 2010-10-14 Morphotek, Inc. Endosialin binding molecules

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005086713A2 (en) * 2004-03-04 2005-09-22 Kirin Brewery Co., Ltd. Role of human endothelial precursor cells and vascular pericytes tumor in angiogenesis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRADY J. et al, Human Endosialin (Tumor Endothelial Marker 1) is Abundantly Expressed in Highly Malignant and Invasive Brain Tumors, Journal of Neuropathology and Experimental Neurology, 2004, Vol. 63(12), pg. 298-208 *
MARTY C. et al, Isolation and characterization of a scFv antibody specific for tumor endothelial marker 1 (TEM1), a new reagent for targeted tumor therapy, Cancer Letters, 2006, Vol. 235, pg. 298-308 *

Also Published As

Publication number Publication date
BRPI0809665B1 (pt) 2021-03-23
CA2682726C (en) 2017-05-09
MX2009010701A (es) 2010-01-20
WO2008124570A1 (en) 2008-10-16
CA2682726A1 (en) 2008-10-16
PT2137217E (pt) 2014-03-20
CY1115370T1 (el) 2017-01-04
AU2008237296A1 (en) 2008-10-16
BRPI0809665B8 (pt) 2021-05-25
PL2620451T3 (pl) 2017-06-30
US20080248034A1 (en) 2008-10-09
JP2013150618A (ja) 2013-08-08
RS55447B1 (sr) 2017-04-28
BRPI0809665A2 (pt) 2018-12-04
PL2137217T3 (pl) 2014-08-29
US9505842B2 (en) 2016-11-29
RS53362B (sr) 2014-10-31
LT2620451T (lt) 2017-01-10
JP2010523592A (ja) 2010-07-15
CN101918446B (zh) 2014-06-18
JP5825784B2 (ja) 2015-12-02
US8895000B2 (en) 2014-11-25
CY1118592T1 (el) 2017-07-12
HRP20140266T1 (hr) 2014-04-25
EP2137217A1 (en) 2009-12-30
DK2620451T3 (da) 2017-01-02
EP2620451A1 (en) 2013-07-31
DK2137217T3 (en) 2014-03-17
SI2620451T1 (sl) 2017-01-31
ES2606906T3 (es) 2017-03-28
US20150079104A1 (en) 2015-03-19
PT2620451T (pt) 2016-12-20
CN101918446A (zh) 2010-12-15
SI2137217T1 (sl) 2014-07-31
HRP20161715T1 (hr) 2017-02-10
KR20100016221A (ko) 2010-02-12
US7807382B2 (en) 2010-10-05
EP2137217B1 (en) 2014-03-05
ES2452929T3 (es) 2014-04-03
KR101529334B1 (ko) 2015-06-16
US20170029509A1 (en) 2017-02-02
US20110033455A1 (en) 2011-02-10
WO2008124570A8 (en) 2008-11-27
HUE031269T2 (en) 2017-06-28
US10053509B2 (en) 2018-08-21
EP2620451B1 (en) 2016-09-14

Similar Documents

Publication Publication Date Title
AU2008237296B2 (en) Methods for inhibiting the binding of endosialin to ligands
US12006371B2 (en) Humanized anti-MUC1* antibodies
CN101189264A (zh) M-csf特异性单克隆抗体及其应用
WO2008044754A1 (en) Prophylactic or therapeutic agent for cancer
KR20210142638A (ko) Cd3 항원 결합 단편 및 이의 응용
JP2015145397A (ja) 抗α２インテグリン抗体を使用する処置
JP5319051B2 (ja) Ａ３３抗原およびｊａｍ−ｉｔの使用
CN112079924B (zh) Pd-l1靶向结合剂及其用途
JP2023529557A (ja) 抗ｅｎｐｐ１抗体の阻害
WO2020248156A1 (zh) Pd-l1靶向结合剂及其用途
RU2776121C2 (ru) Новые анти-pd-l1 антитела
HK1138603A1 (en) Prlr-specific antibody and uses thereof
HK1138603B (en) Prlr-specific antibody and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: EISAI, INC.

Free format text: FORMER OWNER(S): MORPHOTEK, INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired